Literature DB >> 10713691

Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models.

M H Jamerson1, M D Johnson, R B Dickson.   

Abstract

Recent progress in the study of c-Myc has convincingly demonstrated that it possesses a dual role in regulating both proliferation and apoptosis; however, the manner in which c-Myc influences these cellular response pathways remains incompletely characterized. Deregulation of c-Myc expression, via many mechanisms, is a common feature of multiple cancers and is an especially prominent feature of many breast cancers. Of significant interest to those who study mammary gland development and neoplasia is the unresolved nature and contribution of apoptosis to breast tumorigenesis. Recently, the use of transgenic mice and gene-knockout mice has allowed investigators to evaluate the pathological mechanisms by which different genes influence tumor development and progression. In this review, we address two distinct c-myc-containing bitransgenic murine mammary tumor models and discuss the contribution and possible future directions for resolution of cancer-relevant molecular pathways influenced by c-Myc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713691     DOI: 10.1038/sj.onc.1203268

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  Interrogating mouse mammary cancer models: insights from gene expression profiling.

Authors:  Antonio A Fargiano; Kartiki V Desai; Jeffrey E Green
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

2.  Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Peng Guo; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2011-03-02       Impact factor: 5.157

3.  eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

Authors:  Shahram Khosravi; Kevin J Tam; Gholamreza S Ardekani; Magdalena Martinka; Kevin J McElwee; Christopher J Ong
Journal:  J Invest Dermatol       Date:  2015-01-06       Impact factor: 8.551

Review 4.  Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.

Authors:  N E Hynes; H A Lane
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

Review 5.  c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?

Authors:  Claudio Napoli; Lilach O Lerman; Filomena de Nigris; Vincenzo Sica
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

6.  c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.

Authors:  D-W Wu; N-Y Hsu; Y-C Wang; M-C Lee; Y-W Cheng; C-Y Chen; H Lee
Journal:  Oncogene       Date:  2014-06-09       Impact factor: 9.867

Review 7.  Of mice and Myc: c-Myc and mammary tumorigenesis.

Authors:  M Hunter Jamerson; Michael D Johnson; Robert B Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

8.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.

Authors:  Teresa A Rose-Hellekant; Lisa M Arendt; Matthew D Schroeder; Kennedy Gilchrist; Eric P Sandgren; Linda A Schuler
Journal:  Oncogene       Date:  2003-07-24       Impact factor: 9.867

10.  c-myc amplifications in primary breast carcinomas and their local recurrences.

Authors:  S Aulmann; N Adler; J Rom; B Helmchen; P Schirmacher; H P Sinn
Journal:  J Clin Pathol       Date:  2006-02-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.